Companies
Martin Christ
with more than 75 years in the field, it delivered its 30,000th freeze dryer, an Epsilon 2-10D LyoLift, to Coriolis Pharma in April 2026; its LyoCoN controlled nucleation triggers ice at -4 °C and its platforms lyophilize viral vectors such as AAV and lentiviral vectors.
- Country
- Germany
Commercial
LyoCoN Controlled Nucleation
Coverage
| CN | EU | US | |
|---|---|---|---|
| fill-finish-packaging | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Public funding of €194,414 for RUENNA project (Dec 2021) and EU funding of €838,166 for cooling system refurbishment (Oct 2022) | northdata.com |
| Headcount | Approximately 60 to 61 employees as of mid-2026 medium confidence | deubiz.com · die-deutsche-wirtschaft.de · bionity.com |
| Revenue | Estimated annual revenue of €15 million or $1M–$10M medium confidence | die-deutsche-wirtschaft.de |
| Certification | Products meet FDA requirements and cGMP considerations | martinchrist.de |
| Production site | Osterode am Harz, Germany | martinchrist.de |
| Capacity | Manufacturing capacity expanded systematically to produce 30,000 freeze dryers as of 2026; production systems cover sizes from 1 to 13 m2 | martinchrist.de |
Independent sources: bionity.com · deubiz.com · die-deutsche-wirtschaft.de · northdata.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Lyophilizers and freeze dryers | fill-finish-packaging | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.